PELNSEPiramal Enterprises Limited· PharmaceuticalsLowNeutral
Announced Wed, 9 Jul · 17:27 IST

The Exchange had sought clarification from Piramal Enterprises Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. The company has not submitted declaration in case of unmodified opinion(s) The response of the Company is enclosed.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

NSE had asked why Piramal Enterprises did not submit the declaration of unmodified opinion along with its Q4 FY25 results. The company replied that the audited financial results along with the unmodified opinion declaration were actually submitted to the exchanges on 6th May 2025, and attached them for reference. Along with the clarification, the company shared the full board meeting outcome from 6th May 2025, which approved the audited standalone and consolidated results for FY25. The board also recommended a final dividend of Rs. 11 per share (550%) on a face value of Rs. 2, subject to shareholder approval. Standalone FY25 profit after tax came in at Rs. 503.73 crore (vs Rs. 474.05 crore in FY24), with total income of Rs. 2,257.94 crore. Consolidated total income for FY25 was Rs. 10,611.86 crore. The company also highlighted that its subsidiary Piramal Finance Limited received NBFC-ICC registration from the RBI on 4 April 2025, and a Composite Scheme of Arrangement has been filed with NCLT.

Likely market impact

This is a routine procedural clarification confirming that all required SEBI disclosures for Q4 FY25 were submitted on time, so no compliance issue exists. Shareholders get a Rs. 11 per share final dividend (550%), and the company's FY25 profitability held up despite a small Q4 standalone loss of Rs. 23.33 crore, which is largely a technical matter.